SCHEMBL3699840

SCHEMBL3699840

Nc1ccc(S(=O)(=O)N2C3CCCC2CC3)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 5/20 0.49
MMP2 P08253 1/20 0.49
PSEN1 P49768 1/20 0.47
PSEN2 P49810 1/20 0.47
APH1B Q8WW43 1/20 0.47
NCSTN Q92542 1/20 0.47
APH1A Q96BI3 1/20 0.47
PSENEN Q9NZ42 1/20 0.47
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
ESR1 P03372 1/20 0.44
TSHR P16473 3/20 0.43
LMNA P02545 2/20 0.43
MPO P05164 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2C9 P11712 1/20 0.43
HTR6 P50406 1/20 0.43
HSD11B1 P28845 1/20 0.43
PKM P14618 2/20 0.42
ALDH1A1 P00352 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2221418 0.81 ACHE (0.49) ACHEMMP2PSEN1PSEN2APH1B
SCHEMBL2220964 0.81 PSEN1 (0.70) ACHEMMP2PSEN1PSEN2APH1B
SCHEMBL2221744 0.79 ACHE (0.50) ACHEMMP2PSEN1PSEN2APH1B
SCHEMBL2220869 0.79 TRPA1 (0.53) ACHEMMP2PSEN1PSEN2APH1B
SCHEMBL2221432 0.79 PSEN1 (0.72) ACHEMMP2PSEN1PSEN2APH1B
SCHEMBL2219745 0.75 ACHE (0.54) ACHEPSEN1PSEN2APH1BNCSTN
SCHEMBL30004987 0.75 MEN1 (0.60) MEN1KMT2ALMNAPKMALDH1A1
SCHEMBL13812162 0.75 ACHE (0.68) ACHEMMP2MEN1KMT2AHSD11B1
SCHEMBL29551906 0.74 MEN1 (0.67) MEN1KMT2ALMNAPKMALDH1A1
SCHEMBL25317014 0.74 ALDH1A1 (0.43) ACHEPSEN1PSEN2APH1BNCSTN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1836200-B1 BENZISOTHIAZOLE-1, 1-DIOXIDE ACTING AS ANTAGONISTS TO THE VANILLOID RECEPTOR SUBTYPE 1 (VR1) AND USES THEREOF ABBOTT LAB (US) 2012-05-16 EP disclosed
US-7615570-B2 Antagonists to the vanilloid receptor subtype 1 (VR1) and uses thereof ABBOTT LABORATORIES (US) 2009-11-10 US disclosed
US-20060148867-A1 Antagonists to the vanilloid receptor subtype 1 (VR1) and uses thereof ABBVIE INC. 2006-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060148867-A1 Antagonists to the vanilloid receptor subtype 1 (VR1) and uses thereof AVPR1A, AVPR1B, AVPR2 ACHE 1332/4885MMP2 2238/4885PSEN1 3358/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.